Skip to main content
Fig. 4 | Cancer Imaging

Fig. 4

From: Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided microwave ablation in the treatment of small hepatocellular carcinoma

Fig. 4

Kaplan–Meier progression-free survival (PFS) of the TACE alone group compared with the TACE-MWA group. The mean PFS was 21.076 months (95% CI:17.458, 24.693) in the TACE group compared with 28.216 months (95% CI: 24.793, 31.640) in the TACE-MWA group. The median PFS was 19.000 months (95% CI: 10.110, 27.890) in the TACE group compared with 29.000 months (95% CI: 24.786, 33.214) noted in the TACE-MWA group (P = 0.019, log-rank test)

Back to article page